What "Pediatric Dermatologist Tested" Actually Requires: Test Population, Site, Duration and the Documentation Buyers Should Demand
Pediatric dermatologist tested is a claim about a study, not a certificate. Four fields decide whether it holds: the test population, the site, the duration and the report behind it. No market gives the phrase a legal definition. The EU Technical Document on Cosmetic Claims reads "dermatologically tested" as a product tested on humans under a dermatologist's supervision. It applies the same logic to any other medical discipline. That one paragraph is the legal floor, and it turns the claim into a buyer checklist.
DEVA Skincare has manufactured baby and sensitive skin products for 20 years. Four factories carry 20 million units of monthly capacity. We open every claim review with the protocol. The wording has to follow the evidence, not the other way round.
What Does a Pediatric Dermatologist Tested Claim Actually Mean?
The claim carries 1 promise: a dermatologist supervised testing on human subjects and the product passed. It describes who watched the test. It says nothing about the result, the panel size or the endpoint. That gap is why a pediatric dermatologist tested claim needs the report attached before a buyer accepts it.
The EU Technical Document on Cosmetic Claims also rules out consumer self-perception studies as support for this wording. A panel that liked the texture cannot stand in for supervised human testing. The claim narrows to one route: a clinical protocol, a supervising dermatologist and a signed report.
Wording | What it implies | What supports it | What it does not prove |
Pediatric dermatologist tested | A dermatologist supervised human testing | A study report signed by the supervising dermatologist | That every child will tolerate the product |
Pediatrician tested | A paediatrician reviewed the product or the design | A signed review statement | Allergenicity or any patch test result |
Tolerance tested | The product was well tolerated by a target group | A tolerance study with a stated result | Sensitisation across repeated use |
Clinically tested | Human testing under a qualified professional | A clinical protocol and a study report | A specific measured effect |
Hypoallergenic | A formula designed for low allergy risk | Allergen review, screening, patch test and HRIPT | Zero reactions in every user |
Who Has to Be in the Test Population?
Age is the first field in the protocol, and 2 sources set it. ICH E11(R1) fixes the paediatric bands. The brief fixes the target user. That same guideline dates from July 2017 and splits children into 5 bands. Those bands run from newborn to adolescent, and the 3 youngest sit under age 11. A pediatric dermatologist tested claim on a baby lotion has to name the band it covers.
Panel size follows the endpoint. An HRIPT panel runs from 50 to 200 subjects. A closed patch test on 30 to 50 subjects is enough for acute irritation. A 28 day use test on 30 to 120 subjects covers tolerance in normal use. The protocol should also fix the skin type mix and the atopic history. A mixed panel says little about atopic skin.
Two ethics limits shape the panel. A controlled patch test or a use test on infants is neither ethical nor practical. The claim has to stand on in vitro work, adult panels and the published record. In the EU, a skin compatibility study on a finished cosmetic is not a clinical trial. Article 2(2) of Regulation (EU) No 536/2014 puts it outside that framework. It needs no research ethics committee approval. It still runs under the Declaration of Helsinki with written informed consent and adverse event reporting.
Population field | What a buyer should read | Why it decides the claim |
Age band | A named ICH E11(R1) band: 0 to 27 days, 28 days to 23 months or 2 to 11 years | The target user defines the target population |
Panel size | A number plus the drop-out rate | An HRIPT carries weight at 50 to 200 subjects |
Skin type | Fitzpatrick range or stated atopic history | A mixed panel does not prove tolerance on atopic skin |
Exclusion criteria | Written, strict and applied | Active dermatitis, pregnancy and nursing are excluded |
Control | The same base without the active, or an untreated site | Without a control the routine and the formula blur |
Where Does a Pediatric Dermatologist Tested Study Have to Run?
The site decides how much the result is worth, and 4 site types appear in practice. Each one answers a different question. A buyer who sees only the conclusion cannot tell which one produced it.
The EU Technical Document on Cosmetic Claims adds 3 conditions that apply to every site. The person running the study needs the right qualifications, training and experience. The facility needs a quality assurance system with standard operating procedures. Each study needs its own monitoring system, and a report signed by the person in charge.
Site for a pediatric dermatologist tested study | What it proves | What it cannot prove | Cost driver |
In vitro and in chemico laboratory | Sensitisation and irritation potential before human contact | Human tolerance | Assay panel size |
Contract research dermatology unit | Patch test, HRIPT and use test on a recruited panel | Clinical relevance beyond the protocol | Panel size and reading days |
Hospital dermatology department | Supervision by a board-certified dermatologist | Speed, because recruitment runs slower | Clinician time |
Manufacturer laboratory | Formula control, batch records and process checks | Independent human evidence | Internal, no third-party cost |
How Long Does the Study Have to Run?
Duration follows the endpoint, and 4 windows cover almost every baby skincare claim. The shortest study measures acute irritation. The longest measures tolerance across a month of normal use. One pediatric dermatologist tested package usually runs several protocols side by side.
Two protocol details matter more than the headline length. An HRIPT applies 9 patches over 3 weeks. It rests for 10 to 14 days. Then it re-challenges a naive site, with readings at 48, 72 and 96 hours. That challenge reading is the one that detects sensitisation. The older human maximisation test, with 5 inductions on 25 subjects over 10 days, is out of use. The SCCS Notes of Guidance also hold that human testing cannot identify a sensitisation hazard on its own. An HRIPT confirms a low-risk safety assessment instead of replacing it.
Protocol in a pediatric dermatologist tested package | What it answers | Panel | Window |
Closed patch test | Acute irritation under occlusion | 30 to 50 subjects | 24 to 48 hours of occlusion, read at 24, 48 and 72 hours |
Cumulative irritation test | Irritation from repeated contact | 10 to 30 subjects | About 21 days |
HRIPT | Sensitisation after repeated exposure | 50 to 200 subjects | 9 patches over 3 weeks, 10 to 14 days rest, challenge read at 48 to 96 hours |
28 day use test | Tolerance in normal use | 30 to 120 subjects | 4 weeks |
SPF and water resistance | Photoprotection under ISO 24444 and immersion | 10 to 25 subjects | Per the SPF protocol plus immersion cycles |
Which Documents Should a Buyer Demand?
The report is the claim, and 1 document decides it. The EU Technical Document on Cosmetic Claims sets 8 fields for the report. They are product identification, objective, schedule, protocol, results, interpretation, statistics and the signature of the person in charge. A pediatric dermatologist tested claim without that report is marketing copy.
The report also has to identify the tested product well enough to link it to the product on the market. That link is what a brand defends when a regulator or a retailer asks. Batch records from the factory close the loop, because a tested sample proves little if the shipped formula moved.
Document in a pediatric dermatologist tested file | What the buyer reads for | Who holds it |
Dated study protocol | Objective, panel, inclusion and exclusion criteria, readings and endpoints | Testing laboratory |
Ethics statement and consent form | Informed consent under the Declaration of Helsinki | Testing laboratory |
Supervising dermatologist record | Board certification and role, for the file only | Testing laboratory |
Panel composition sheet | Age band, skin type and atopic history per subject | Testing laboratory |
Raw reading sheets | Erythema and oedema scores by subject and visit | Testing laboratory |
Adverse event log | Every reaction, the action taken and the outcome | Testing laboratory |
Final signed report | Results, interpretation, statistics and the signature of the person in charge | Testing laboratory |
Batch and process records | Proof that the tested formula equals the shipped formula | Manufacturer |
Bridging rationale and safety assessment | Why the study covers the marketed product and the age band | Safety assessor |
How Do Pediatrician Tested and Dermatologist Tested Differ?
The 2 phrases name different reviewers, and 1 of them says nothing about allergenicity. Pediatrician tested describes who reviewed the product or the study design. Dermatologist tested describes who supervised testing on human subjects. A pediatric dermatologist tested claim sits at the crossing point, where the reviewer works in paediatric skin and supervised the panel.
The wording also has a limit. The EU Technical Document on Cosmetic Claims blocks phrasing that promises a guaranteed property. A tested claim cannot state that no user will react. Keep the sentence on the study. A paid review is still a review. The FTC Endorsement Guides at 16 CFR Part 255 require disclosure of a material connection. That duty applies when a named endorser was paid.
Which Market Rules Change the Evidence?
Three markets police the claim in 3 ways, and the age definition is not the same in any of them. The EU reads the claim against the finished product. The US asks whether the evidence is competent and reliable. China writes the age limit and the permitted claims into a dedicated regulation.
In the EU, Article 20 of Regulation (EC) No 1223/2009 bans claims a product cannot support. Commission Regulation (EU) No 655/2013 sets 6 common criteria on top of that. One criterion decides this case. Evidence has to match the finished product as marketed. It also has to follow a well-designed and reproducible method and respect ethical considerations. That evidence sits in the product information file under Article 11. The Responsible Person has to hold it before the first unit reaches the market.
In the US, the FTC asks for competent and reliable scientific evidence. Section 5 of the FTC Act is the hook. FDA sets no definition of the phrase. MoCRA adds safety substantiation and adverse event records, not efficacy review. In China, the Children's Cosmetics Supervision and Administration Regulation took effect on 1 January 2022 for every duty except labelling. Labelling followed on 1 May 2022 under NMPA Announcement No. 123 of 2021. Children's cosmetics cover age 12 and under. The permitted claims for children aged 0 to 3 are limited to 6 functions.
A buyer who wants a file shaped like a clinical trial can ask for ICH E6(R3) good clinical practice. The principles and Annex 1 arrived on 6 January 2025. They took effect in the EU on 23 July 2025 and reached FDA final guidance on 9 September 2025. A cosmetic tolerance study does not have to follow that guideline, but the structure helps a retail reviewer.
Market | How the claim is policed | What the file holds | Age rule |
EU | Article 20 of Regulation (EC) No 1223/2009 plus 6 common criteria under Regulation (EU) No 655/2013 | Claim evidence inside the product information file under Article 11 | No children's category, so the evidence has to match the target user |
US | Section 5 of the FTC Act and the competent and reliable evidence standard | MoCRA safety substantiation and adverse event records | No children's category and no FDA definition |
China | Children's Cosmetics Supervision and Administration Regulation, effective 1 January 2022 | Registration or filing, safety assessment and necessary toxicology tests | Children's cosmetics cover age 12 and under, with a shorter claim list for 0 to 3 |
What Does DEVA Skincare Bring to a Pediatric Dermatologist Tested Claim?
DEVA Skincare has run baby and sensitive skin programs for 20 years. It holds 70+ granted patents, plus 22 special cosmetics certificates and 21 more under application. Production runs in a 100,000 grade GMPC cleanroom, and the core laboratories are built to CNAS standards.
The testing bench carries 150 efficacy and safety protocols. Those include cell efficacy and toxicity, the chorioallantoic membrane irritation assay, melanin inhibition and preservative challenge. Six laboratories cover cell testing, product efficacy evaluation and active analysis. Product efficacy evaluation uses VISIA imaging across 12 skin indicators. Active analysis runs on HPLC, GC and UV-Vis. The remaining benches handle extraction, fermentation, packaging ageing and heavy metals. Every batch also clears 72 inspection and process control steps.
Two baby care lines we manufacture each ship about 13 million units a year. That volume is why claim work starts early in the brief. Standard MOQ is 5,000 units per SKU for emulsion and wash formats and 10,000 for aluminium cans. Masks start at 50,000 units, and ampoules at 200,000. Sampling takes 1 week. Mass production starts 6 weeks after sample approval, and each test protocol runs about 4 weeks.
Send the target market, the claim as written and the pack format through the inquiry form on this page. We will turn a pediatric dermatologist tested brief into a protocol. That protocol names the age band, the site, the 4 week window and the 9 documents your buyer should hold. Then we quote against your pack. If you already hold a test report and want a second read, send that too.
Does "pediatric dermatologist tested" have a legal definition?
No. No market defines the phrase, and FDA sets no standard for it. The EU Technical Document on Cosmetic Claims treats "dermatologically tested" as testing on humans under a dermatologist's supervision, and reads the same logic into any other medical discipline. The claim therefore stands on the report behind it, not on the words.
How many subjects does the study need?
Panel size follows the endpoint. An HRIPT panel runs from 50 to 200 subjects, because sensitisation is a low-frequency event. A closed patch test covers acute irritation on 30 to 50 subjects. A 28 day use test covers tolerance in normal use on 30 to 120 subjects.
Can you run a patch test on infants?
No. A controlled patch test or a use test on infants is neither ethical nor practical. Build the file on in vitro screening, adult panels and the published record. In the EU no research ethics committee approval is required for a cosmetic tolerance study, but the Declaration of Helsinki still applies.
How long does the full claim package take?
Plan about 4 weeks per protocol, with most protocols running in parallel. An HRIPT alone needs 3 weeks of induction, a 10 to 14 day rest and a challenge read at 48 to 96 hours. Sampling takes 1 week, and mass production starts about 6 weeks after sample approval.
What is the difference between pediatrician tested and dermatologist tested?
Pediatrician tested names the reviewer, so it says who assessed suitability for paediatric skin. Dermatologist tested names the supervisor of the human testing. A pediatric dermatologist tested claim covers both. Neither phrase describes the result, so a buyer still has to read the report.
What should I ask a supplier for before I accept the claim?
Ask for the dated protocol, the ethics statement, the panel composition sheet, the raw readings, the adverse event log and the final signed report. The report should carry product identification, objective, schedule, protocol, results, interpretation, statistics and the signature of the person in charge. Batch records prove the tested formula shipped.
Is pediatric dermatologist tested the same as hypoallergenic?
No. A pediatric dermatologist tested claim describes who supervised a study. Hypoallergenic describes a formula built to keep allergenicity low, and it needs allergen avoidance plus screening data. One HRIPT supports the first claim. It cannot promise that no user will react.
Comments